CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

BCGWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (2)

Name (Synonyms) Correlation
drug77 Aviptadil (VIP) Wiki 1.00
drug616 Placebo Wiki 0.10

Correlated MeSH Terms (6)

Name (Synonyms) Correlation
D004417 Dyspnea NIH 0.58
D014947 Wounds and Injuries NIH 0.41
D055370 Lung Injury NIH 0.32
D055371 Acute Lung Injury NIH 0.16
D012127 Respiratory Distress Syndrome, Newborn NIH 0.15
D012128 Respiratory Distress Syndrome, Adult NIH 0.13

Correlated HPO Terms (0)

Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials

1 COVID-19: BCG As Therapeutic Vaccine, Transmission Limitation, and Immunoglobulin Enhancement

To date, there is no vaccine or treatment with proven efficiency against COVID-19, and the transmissibility of the SARS-CoV-2 virus can be inferred by its identification in the oro-nasopharynx. The bacillus Calmette Guérin (BCG) has the potential for cross-protection against viral infections. This study evaluates the impact of previous (priming effect, from the titer of anti-BCG interferon-gamma) or current BCG exposure (boost with intradermal vaccine) on 1) clinical evolution of COVID-19; 2) elimination of SARS-CoV-2 at different times and disease phenotypes; and 3) seroconversion rate and titration (anti-SARS-CoV-2 IgA, IgM, and IgG).

NCT04369794 COVID-19 Therapeutic Vaccine BCG SARS-CoV 2 Transmission Biological: BCG Biological: Placebo

Primary Outcomes

Description: Classified as mild, moderate and severe

Measure: Clinical evolution of COVID-19

Time: 45 days of symptoms onset or diagnosis

Description: Virus detection by PCR

Measure: SARS-CoV-2 elimination

Time: 7 days of symptoms onset or diagnosis

Description: Titration of anti SARS-CoV-2 IgA, IgM and IgG

Measure: Seroconversion rate and titration

Time: 7 days of symptoms onset or diagnosis

Secondary Outcomes

Description: Classified according to type and severity

Measure: Local and systemic adverse events to BCG vaccination

Time: 3 months

Other Outcomes

Description: Virus detection by PCR

Measure: SARS-CoV-2 elimination

Time: 21 days of symptoms onset or diagnosis

Description: Titration of anti SARS-CoV-2 IgA, IgM and IgG

Measure: Seroconversion rate

Time: 21 days of symptoms onset or diagnosis

Description: Virus detection by PCR

Measure: SARS-CoV-2 elimination

Time: 45 days of symptoms onset or diagnosis

Description: Titration of anti SARS-CoV-2 IgA, IgM and IgG

Measure: Seroconversion rate and titration

Time: 45 days of symptoms onset or diagnosis

No related HPO nodes (Using clinical trials)